Glaucoma, Vision & Longevity: Supplements & Science podcast

A Steroid Injection During Glaucoma Surgery Was Linked to Dangerous Low Eye Pressure — What a New Randomized Trial Found

0:00
18:52
Manda indietro di 15 secondi
Manda avanti di 15 secondi

This audio article is from VisualFieldTest.com.

Read the full article here: https://visualfieldtest.com/en/a-steroid-injection-during-glaucoma-surgery-was-linked-to-dangerous-low-eye-pressure-what-a-new-randomized-trial-found

Test your visual field online: https://visualfieldtest.com

Support the show so new episodes keep coming: https://www.buzzsprout.com/2563091/support

Excerpt:

A Steroid Injection During Glaucoma Surgery Was Linked to Dangerous Low Eye Pressure — What a New Randomized Trial Found Research checked through November 4, 2026. A small randomized trial published on October 29, 2026, raised a serious safety question: could a long-acting steroid injection given during glaucoma drainage-device surgery suppress healing so much that the eye drains too freely? In the trial, late-onset low eye pressure occurred in 10 of 19 eyes given triamcinolone around the implant, compared with none of 20 control eyes. Seven of the 10 affected eyes needed another operation. That is a striking signal—but it does not show that ordinary steroid eye drops after glaucoma surgery are dangerous, nor that every drainage device or steroid regimen carries the same risk. The study tested one 20-milligram depot injection with one non-valved implant, in a small group of people with difficult-to-control glaucoma. Important details about the pressure threshold, the timing of individual cases, and their recovery are not reported in the publicly available abstract or registry. Trial report on PubMed Trial record on ReBEC What the new randomized trial tested Treatment, injection location, and masking The study included 39 eyes from 39 people with refractory primary open-angle glaucoma. All were undergoing Susanna UF glaucoma drainage-device surgery; the registry says participants had failed at least one prior trabeculectomy. Twenty eyes were assigned to the device alone, and 19 to the device plus triamcinolone. Follow-up lasted six months. The journal describes the study as multicenter and randomized. Trial report on PubMed Trial record on ReBEC The triamcinolone was 20 milligrams: 0.5 milliliters of a 40-milligram-per-milliliter suspension. It was injected into the sub-Tenon’s space around the implant plate, immediately before the conjunctiva—the tissue covering the white of the eye—was closed. This is a depot injection beside the implant, not an injection into the inside of the eye. Trial record on ReBEC The published abstract says that patients and outcome assessors were masked. The registry says a sham injection might have been used to mask the surgeon, but also allows that no sham was performed. So, based on the public records, surgeon masking cannot be confirmed. The registry also does not provide the full surgical recipe: it does not establish whether the tube was tied, fenestrated, or internally stented, or whether mitomycin C was used. Those details matter because they can change how much fluid flows through the device. Trial report on PubMed Trial record on ReBEC There are two further cautions. The registry lists a target of 48 participants, but only 39 were enrolled; recruitment stopped early because of safety concerns. It also records a first enrollment date in December 2020 and a public registration date in July 2025. Late public registration does not prove that results were reported selectively, but it limits confidence that every outcome and analysis was publicly specified before enrollment began. All 39 enrolled participants completed six-month follow-up. Trial record on ReBEC What the trial found For the full table, please open this article on visualfieldtest.com. The injection did not provide an additional pressure-lowering benefit at six months. Average pressure was about 14 mmHg in both groups, and the reduction from baseline was almost identical. A similar group average does not rule out serious low-pressure episodes in individual eyes: averages can hide a wide range of outcomes. Trial report on PubMed The seven operations were performed in seven of the 10 eyes with late-onset hypotony. The public report does not say what procedures were used, when each operation occurred, or whether each eye’s pressure and vision ultimately recovered. Trial record on ReBEC What is—and is not—known about the complications The registry reports these additional events: For the full table, please open this article on visualfieldtest.com. The registry defines a serious-complication group as late hypotony or malignant glaucoma. That composite was 52.6% in the triamcinolone group and 5% in controls. The single control event was malignant glaucoma; it was not a case of late hypotony. The published abstract separately reports late hypotony as 10 of 19 versus zero, and clinically significant hypotony requiring reintervention as seven of 19 versus zero. Trial report on PubMed Trial record on ReBEC The public abstract and registry do not give an exact numerical definition of hypotony or the threshold used to label an event “late-onset.” They also do not give the month each case began or how long it lasted. The registry reports no statistically significant difference in average visual acuity at follow-up, and no event directly related to the intervention led to loss of light perception. But it does not report how many individual patients lost lines of vision, or provide separate counts for choroidal detachment, hypotony-related macular changes, shallow front chamber, or bleb leaks. Those outcomes should be treated as not reported, not as confirmed zero events. Trial record on ReBEC The registry says that de-identified participant-level data may be requested from the investigators, subject to a research proposal and ethics approval. That dataset would be needed to learn the exact case timelines and individual outcomes. Trial record on ReBEC Why might a steroid depot lead to too much drainage? The capsule around an implant helps regulate flow A drainage device carries fluid from inside the eye to tissue around its plate. As healing proceeds, a fibrous capsule forms around that plate. The capsule is not merely scar tissue to eliminate: it also provides much of the resistance that regulates drainage. Too much scarring can restrict flow and raise eye pressure; too little capsule resistance can allow excessive flow and lower pressure too far. American Academy of Ophthalmology overview of drainage devices Evidence supports the general pathway, but not the precise explanation for this trial. A broad review describes how inflammation and fibroblast activity contribute to wound healing and scarring after glaucoma surgery. A separate report described three patients on long-term systemic immune-suppressing treatment who developed persistent hypotony after non-valved implants; their implant capsules were thin and immature. That makes it biologically plausible that strong suppression of healing could reduce capsule resistance. But those cases involved chronic systemic treatment, not a one-time 20-milligram injection of triamcinolone around a Susanna device. The Susanna trial did not measure capsule thickness or fluid flow. Wound-healing review Capsule histology case report The most plausible explanation is therefore an inference: if the depot reduced inflammation and capsule formation around the plate, the outflow pathway may have had less resistance. That could lead to excess drainage, especially once any temporary restriction on tube flow weakens or opens. The trial’s public records do not establish the timing of hypotony relative to tube opening, or even the exact tube-restriction method used. So this mechanism is reasonable, but unproven for these eyes. A depot is not the same as adjustable eye drops A depot injection leaves a suspension near the implant that releases medicine over time. A study of sub-Tenon’s triamcinolone after cataract surgery describes drug delivery lasting several weeks, though the duration can vary. In contrast, eye drops deliver a dose with each use; clinicians can taper or stop them based on the eye’s inflammation and healing. Randomized study of 20-milligram sub-Tenon’s triamcinolone after cataract surgery Crucially, both arms in the Susanna trial received postoperative dexamethasone eye drops—initially six times a day, then gradually reduced over six to eight weeks. The randomized difference was the added depot injection. The trial therefore does not show that routine postoperative steroid drops caused the hypotony signal. It tested a long-acting injection on top of the same drop regimen given to controls. Trial record on ReBEC Steroids can also raise eye pressure in some patients, particularly with prolonged exposure. That is a different effect from the suspected mechanism here: the concern is not that triamcinolone directly lowers pressure inside the eye, but that it might change wound healing and reduce resistance around a drainage pathway. How the findings compare with other glaucoma surgeries For the full table, please open this article on visualfieldtest.com. Why the results may differ Valved versus non-valved devices. The Ahmed valve is designed to restrict flow as pressure becomes low. Susanna UF and Baerveldt implants are non-valved, so they lack that same built-in valve. Non-valved implants are commonly managed with temporary tube ligatures, stents, or other flow-control steps, but the Susanna trial’s public records do not say exactly which were used. In a pooled analysis of three randomized tube-surgery trials, chronic hypotony was uncommon overall—4.1% by five years—but the risk was higher

Support the show

Altri episodi di "Glaucoma, Vision & Longevity: Supplements & Science"